Skip to main
TYRA

Tyra Biosciences (TYRA) Stock Forecast & Price Target

Tyra Biosciences (TYRA) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tyra Biosciences Inc is strategically positioned to capitalize on a significant market opportunity exceeding $10 billion in bladder cancer and bone growth disorders, supported by robust clinical data that strengthens the therapeutic rationale for selective FGFR3 inhibition. The company has increased its probability of approval for its lead drug candidates in achondroplasia and hypochondroplasia from 35% to 40%, as competitive validation diminishes risks associated with its product pipeline. With an innovative precision medicine platform, SNAP, enabling efficient drug design and a focus on enhancing patient outcomes through superior efficacy and tolerability compared to existing treatments, Tyra's pipeline holds promise for establishing best-in-class therapies in targeted oncology.

Bears say

Tyra Biosciences Inc faces significant risks that contribute to a negative outlook on its stock, including potential delays and negative clinical data associated with its main drug candidates, TYRA-300 and TYRA-200. The company also encounters challenges related to achieving regulatory approval and the commercial uptake of its products, which may be further exacerbated by competition and the effectiveness of newly approved treatments like JELMYTO. Additionally, the possibility of medium- to long-term dilution poses another layer of concern that could impact investor confidence and financial stability.

Tyra Biosciences (TYRA) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tyra Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tyra Biosciences (TYRA) Forecast

Analysts have given Tyra Biosciences (TYRA) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Tyra Biosciences (TYRA) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tyra Biosciences (TYRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.